Fertility Preservation Discussions Between Young Adult Rectal Cancer Survivors and Their Providers: Sex-Specific Prevalence and Correlates

Julia Stal(Dana-Farber Cancer Institute), Kimberly A. Miller(University of Southern California), Joel Milam, Heinz‐Josef Lenz(University of Southern California), Serena Y Yi(Keck Hospital of USC), Afsaneh Barzi(City Of Hope National Medical Center), Sally Cohen‐Cutler(Children's Hospital of Los Angeles), David R. Freyer(University of Southern California), Phuong Gallagher(Army and Navy Club)

The Oncologist

February 24, 2022

10.1093/oncolo/oyac052

Cited by 24

Related Papers

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

|The Lancet Oncology|2017|2.8k

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

|Journal of Clinical Oncology|2018|2.1k

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer

|JAMA|2017|891

Prognostic and Predictive Relevance of Primary Tumor Location in Patients With <i>RAS </i>Wild-Type Metastatic Colorectal Cancer

|JAMA Oncology|2016|722

Randomized Study of Two Chemotherapy Regimens for Treatment of Low-Grade Glioma in Young Children: A Report From the Children's Oncology Group

|Journal of Clinical Oncology|2012|433